A Tumor Necrosis Factor inhibitor is a pharmaceutical drug used to destroy the physiologic response to tumor necrosis factor such as inflammatory response caused by TNF cytokines. A major component of the autoimmune system such as TNF- alpha is responsible for inflammation in the body. TNF inhibitors are antibodies made in a lab from human or animal tissue. Once they're put into human blood, they cause a reaction in immune system that blocks inflammation. Immune system makes a substance called tumor necrosis factor (TNF). If the body start making too much TNF, and that leads to inflammation. Inflammation that's out of control can damage body and might have pain or swelling. These drugs block the action of TNF. TNF inhibitor widely used for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, crohn’s disease, cancer, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma. Recently, five inhibitors are available in the tumor necrosis factor inhibitor market such as Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Certolizumab (Cimzia), and Golimumab (Simponi). These are prescribed only for autoimmune diseases such as rheumatoid arthritis, crohn’s disease, and psoriasis. But this TNF inhibitors have many side effect like redness, burning, or itching where the needle goes into skin and Other possible side effects such as Coughing, Headaches, Heartburn, Nausea or vomiting, Stomach pain, Weakness. This factors hamper the market growth.
COVID-19 Scenario Analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
As the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries across the globe with the “World Health Organization” announcing it a public health emergency. The global impacts of the COVID-19 pandemic are already starting to be felt, and will significantly affect the tumor necrosis factor inhibitor market in 2020. COVID-19 can affect the global economy in three main ways by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:
Humira hold the largest market share and continues to be one of the top-selling pharmaceutical products across the globe. According to WHO, Humira is anticipated to be at top of the TNF inhibitor products through to 2026.
Globally, North America hold the largest market share due to the strong commercial sales of TNF inhibitors in U.S. other factors contributing to the growth such as the presence of market player, increasing number of government initiative, favourable reimbursement policies, and increasing patient pool. Whereas, Asia Pacific is expected to expand the largest market share, increasing development in economic, increasing autoimmune disease, increasing development in healthcare infrastructure, growing in customer awareness, increasing geriatric population,
In 2017 “Centers for Disease Control and Prevention” (CDC), stated that approximately 54.4 million people are suffering from arthritis in the U.S. as per the report of “National Center for Biotechnology Information” (NCBI), 50% of the population suffering from autoimmune diseases across the globe, discontinue the use of TNF inhibitors after one year of use as only 5-10% of the population showed positive response to TNF inhibitors while the remaining people show disease activity or severe side effects even after the treatment with TNF inhibitors.
The factor that drive the tumor necrosis factor inhibitor market such as increasing number of new product launches, growing prevalence of autoimmune diseases, increasing geriatric population, favourable government initiative, rising investment in R&D, and healthcare sector, increasing awareness among the population regarding tumor necrosis factor (TNF), rising demand for advanced product for treating autoimmune disease, increasing R&D activities. However the factor such as high cost of treatment and product of rheumatoid arthritis, low number of R&D activities restrain the growth of tumor necrosis factor inhibitor market. The opportunities available for tumor necrosis factor inhibitor market such as in favourable government initiative by introducing reimbursement policies, increasing R&D activities for launching advanced product, rising awareness amongst the people regarding technologically advanced treatment and product development.
New Product launch to flourish the market:
Major Key market manufacturer have been focusing on increasing research and development activities and producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications. Humaira is the most widely prescribed drug for tumor and rheumatoid arthritis disorders. Various biosimilar versions of Humira, Enbrel, and Remicade have been launched such as Erelzi, Inflectra, Cyltezo, Flixabi, Zessly, Hyrimoz, and Amgevita.
In 2019, “Celgene Corporation” has received the U.S. FDA approval for “Otezla” an oral PDE4 inhibitor for the treatment of adult patients with mouth ulcers associated with behçet’s disease, a rare disorder that causes blood vessel inflammation throughout the body. Otezla is the first drug to be approved for this use in the U.S., providing a treatment option for behçet’s disease, many of whom develop mouth ulcers as a result of the condition.
In 2019, “Novartis AG has launched” “Etanercept- Szzs” is a biosimilars of “Etanercept manufactured by “Amgen” this biosimilar used for the treatment of autoimmune disorders.
In 2019, “Samsung Bioepis Co., Ltd,” has recived U.S.FDA approval for “Eticovo”. This is the second biosimilar of Enbrel, which is beneficial for patients suffering from arthritis and cannot work properly with their limbs.
In 2018, “Merck & Co.” has launched “Renflexis” biosimilar of infliximab. This biosimilar is used to treat various types of arthritis such as rheumatoid arthritis, arthritis of the spine, psoriatic arthritis, certain bowel diseases including Crohn's disease, ulcerative colitis and a certain severe skin disease including chronic plaque psoriasis.
In 2017, “Pfizer Inc.” has launched “Xeljanz” a Janus kinase inhibitor which is a small molecular drug for rheumatoid arthritis.
In 2019, “Amgen Inc.” also announced the U.S. FDA approval for “AVSOLA”. AVSOLA is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. AVSOLA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.
Key benefits of the report:
- This study presents the analytical depiction of the global tumor necrosis factor inhibitor market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global tumor necrosis factor inhibitor market share.
- The current market is quantitatively analyzed to highlight the global tumor necrosis factor inhibitor market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global tumor necrosis factor inhibitor market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Tumor Necrosis Factor Inhibitor Market research report:
- Who are the leading market players active in tumor necrosis factor inhibitor market?
- What are the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the tumor necrosis factor inhibitor market?
- What are the projections for the future that will help in taking further strategic steps?
Tumor Necrosis Factor Inhibitor Market, by Product Report Highlights
| Aspects | Details |
 By Product |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Merck and co., Inc., Bristol-Myers Squibb Company, UCB S.A., GlaxoSmithKline plc., Johnson and Johnson Services, Inc., Cadila Healthcare Ltd, AbbVie Inc., Novartis International AG, Pfizer, Inc., Amgen Inc., Sanofi S. A |
Loading Table Of Content...
